Abivax S.A. income statement AAVXF

Annual Quarterly

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
Weighted average shares, basic
70
+10.3%
63
+46.4%
43
Weighted average shares, diluted
70
+10.3%
63
+46.4%
43
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ABVX (Nasdaq), AAVXF (OTC)
Fiscal year ends
December 31
Incorporated in
France
Headquarters
Paris
SEC filer status
Accelerated filer, Emerging growth company
SEC CIK
1956827

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.